NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03321539,Phase â…¢ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma,https://clinicaltrials.gov/study/NCT03321539,,ACTIVE_NOT_RECRUITING,To see the effect if a combination of concurrent chemoradiotherapy followed by different adjuvant chemotherapy in treating patients with N2-3 nasopharyngeal carcinoma(NPC).,NO,Nasopharyngeal Carcinoma,DRUG: CCRT+GP|DRUG: CCRT+PF,"Progress-free survival(PFS), Progress-free survival is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up., 3 years","Overall survival(OS), The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up., 3 years|Locoregional failure-free survival(LRRFS), The LRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit., 3 years|Distant metastasis-free survival(DMFS), The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit., 3 years|Overall response rate, Tumour response was classified according to RECIST, version 1.1, 16 weeks after completion of concurrent chemoradiotherapy|Incidence of acute and late toxicity, Incidence of acute toxicity is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria. Late radiation toxicities were assessed using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme, 3 years",,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE3,216,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-FXY-077,2017-10-30,2022-12-25,2025-12-31,2017-10-25,,2023-05-22,"Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou,, Guangdong, 510000, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China|The Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, Guizhou, 550000, China|The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, Hunan, 410000, China",
